Analysts expect Mediwound Ltd (NASDAQ:MDWD) to report $970,000.00 in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Mediwound’s earnings, with the highest sales estimate coming in at $1.14 million and the lowest estimate coming in at $740,000.00. Mediwound posted sales of $690,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of 40.6%. The company is expected to report its next quarterly earnings results on Thursday, August 2nd.
On average, analysts expect that Mediwound will report full year sales of $3.56 million for the current year, with estimates ranging from $2.79 million to $3.90 million. For the next financial year, analysts anticipate that the company will report sales of $11.69 million per share, with estimates ranging from $5.81 million to $14.80 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Mediwound.
Get Mediwound alerts:Mediwound (NASDAQ:MDWD) last posted its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.17). The company had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.57 million. Mediwound had a negative net margin of 904.12% and a negative return on equity of 226.62%.
Several research firms have weighed in on MDWD. ValuEngine upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a report on Friday, June 1st. Zacks Investment Research lowered shares of Mediwound from a “hold” rating to a “sell” rating in a report on Wednesday. Oppenheimer set a $14.00 target price on shares of Mediwound and gave the stock a “buy” rating in a report on Monday, June 11th. Finally, Wells Fargo & Co reiterated a “buy” rating on shares of Mediwound in a report on Tuesday, May 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. Mediwound currently has a consensus rating of “Buy” and a consensus target price of $9.29.
Large investors have recently modified their holdings of the stock. Meitav Dash Investments Ltd. acquired a new stake in shares of Mediwound during the fourth quarter worth $2,184,000. Wells Fargo & Company MN raised its holdings in shares of Mediwound by 84.6% during the fourth quarter. Wells Fargo & Company MN now owns 101,189 shares of the biopharmaceutical company’s stock worth $450,000 after acquiring an additional 46,366 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Mediwound by 18.2% during the fourth quarter. Renaissance Technologies LLC now owns 100,600 shares of the biopharmaceutical company’s stock worth $448,000 after acquiring an additional 15,500 shares during the period. Institutional investors and hedge funds own 32.78% of the company’s stock.
MDWD opened at $6.45 on Friday. The firm has a market capitalization of $185.28 million, a price-to-earnings ratio of -10.40 and a beta of -0.09. Mediwound has a twelve month low of $3.56 and a twelve month high of $7.50.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Get a free copy of the Zacks research report on Mediwound (MDWD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment